MedTrace Logo

Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study

NCT04594746 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-02-05

No results posted yet for this study

Summary

The investigators will seek to determine the safety and efficacy of high-dose amiodarone (2000mg), given as a single uniform oral dose, for the treatment of acute atrial fibrillation in both a hospital inpatient and ambulatory outpatient setting. The investigators will conduct a placebo-controlled randomized trial, with outcome ascertainment at 48h.

Conditions

Interventions

DRUG

Amiodarone Hydrochloride

Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food

DRUG

Placebo

Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Satish R Raj, MD MSCI · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-03
Primary Completion
2026-01-20
Completion
2026-01-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594746 on ClinicalTrials.gov